Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Risk of stroke, gangrene from ergot drug interactions

Eric Wooltorton
CMAJ April 15, 2003 168 (8) 1015;
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Dihydroergotamine and ergotamine are ergot alkaloids commonly used to treat migraines.1 Many clinicians may be unaware of recently recognized interactions of these ergot derivatives with several commonly used antibiotic, antiviral and antifungal drugs.2

The drugs: Ergot alkaloids are derived from the grain fungus Claviceps purpurea. In the Middle Ages, contaminated grain caused plagues of ergotism characterized by gangrene and an intense peripheral burning pain (known as “St. Anthony's fire”), spontaneous abortion and occasional episodes of mania and hallucinations.3 Initially used therapeutically by European midwives to hasten labour (with many untoward effects), ergot derivatives eventually found a life-saving role in the treatment of post-partum hemorrhage.3 Ergotamine was first used in the treatment of acute migraine in 1926.4

Unlike triptan medications, which have a more selective affinity for serotonin 5-HT1 receptors, ergotamine and dihydroergotamine are nonselective 5-HT1 agonists.1 They also have affinities for dopamine and noradrenaline receptors.4 Common adverse effects of ergotamine and dihydroergotamine are nausea, vomiting, abdominal pain, diarrhea, peripheral paresthesias, swollen fingers, generalized weakness, and peripheral and coronary vasoconstriction.4 The drugs are contraindicated in people with peripheral vascular disorders, coronary artery disease, stroke, severe hypertension, pregnancy, hepatic or renal failure, or sepsis.4

Ergotamine and dihydroergotamine are metabolized in the liver by the cytochrome P450 (CYP) 3A4 enzyme. Several medications (see box) are CYP 3A4 inhibitors and slow the metabolism of ergotamine, causing serious toxic effects, including stroke, gangrene and death.2,5,6 Other CYP 3A4 inhibitors, such as grapefruit juice,7 and drugs including heparin, cyclosporine, tacrolimus and ampicillin present at least the theoretical possibility of drug interactions.8 Ergotamine and dihydroergotamine are marketed in Canada in several preparations, including Migranal, Cafergot and Bellergal.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

What to do: Physicians are often unaware of all the medications their patients take, especially those prescribed by other physicians and those taken only intermittently. Thus, common CYP 3A4 inhibitors (see box) may inadvertently be prescribed to patients taking ergot derivatives, increasing their risk of serious adverse effects. Other migraine therapies could be considered. Physicians prescribing ergot-related drugs should advise their patients to watch for persistent numbness, tingling, ice-cold limbs, muscle cramps and weakness, and to seek medical attention if these occur.

Eric Wooltorton CMAJ

References

  1. 1.↵
    Pryse-Phillips WE, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, et al. Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ 1997;156 (9): 1273-87.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    New contraindication regarding ergotamine- and dihydroergotamine-containing drugs: risk of cerebral and/or peripheral ischemia [Dear Healthcare Professional Letter]. Dorval: Novartis Pharmaceuticals Canada Inc.; Jan 2003. Available: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/ergotamine_e.pdf (accessed 2003 Mar 18).
  3. 3.↵
    De Costa C. St Anthony's fire and living ligatures: a short history of ergometrine. Lancet 2002; 359:1768-70.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000;123:9-18.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38(1):41-57.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW. Fatal ergotism induced by an HIV protease inhibitor. Headache 2002;42(7):694-5.
    OpenUrlPubMed
  7. 7.↵
    Maskalyk J. Grapefruit juice: potential drug interactions. CMAJ 2002;167(3):279-80.
    OpenUrlFREE Full Text
  8. 8.↵
    Eadie MJ. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 2001;15:105-18.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 168, Issue 8
15 Apr 2003
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Risk of stroke, gangrene from ergot drug interactions
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Risk of stroke, gangrene from ergot drug interactions
Eric Wooltorton
CMAJ Apr 2003, 168 (8) 1015;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Risk of stroke, gangrene from ergot drug interactions
Eric Wooltorton
CMAJ Apr 2003, 168 (8) 1015;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Holy fire in an HIV-positive man: a case of 21st-century ergotism
  • Google Scholar

More in this TOC Section

Practice

  • Infected atrial myxoma presenting with purpura
  • Mild bleeding disorders in adults
  • Cerebral venous and sinus thrombosis with complicating thromboangiitis obliterans
Show more Practice

Health and Drug Alerts

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Neurology
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire